The results of studies of long-term effects of population exposure in the South Urals in the 1950s were based for a long time on studies of the effects of exposure in the Techa River cohort and later in the East Urals Radioactive Trace cohort. After the creation of the South Urals Population Exposed to Radiation cohort, combining all persons exposed in the South Urals in the period from January 1, 1950, to December 31, 1960 the size of the cohort doubled, follow-up period reached 71 years, and the number of person-years at risk increased to 1,964,333. The average dose to red bone marrow for all cohort members was 231mGy. Regression analysis using a simple parametric excess relative risk model was performed using the EPICURE statistical package. The analysis resulted in confirmation of a statistically significant (p <0.001) linear doseresponse relationship of mortality for all hemoblastoses, and leukemia. The excess relative risk and 95% confidence intervals of death at 2-year latency period from all hemoblastoses were 0.71/Gy (0.28;1.31); from all leukemias - 1.28/Gy (0.55-2.39) and from leukemias excluding chronic lymphocytic leukemia -1.52/Gy (0.64-2.94). The quadratic model also significantly described the dose dependence; (the differences between the models were not significant). Increasing the follow-up period to 71 years resulted in a slight decrease in risk estimates. The width of the confidence intervals of the risk estimates decreased by more than a factor of 3 compared to earlier studies in the Techa River cohort, which indicates a decrease in uncertainties of risk estimates. Increasing the size of the cohort made it possible to obtain significant risk values for individual population groups (by sex, age, etc.). Analysis of risk values modification did not reveal significant differences in dose dependence on the studied factors, including attained age and age at exposure. The study will be continued to investigate in more detail the influence of time-dependent factors on dose dependence, as well as to assess the risk of death from different cellular forms of leukemia.